|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | HemCon Medical Technologies Inc., a manufacturer of woundcare technologies to control bleeding and infection resulting from trauma or surgery. |
|---|---|
| Transferring Party | Alltracel Pharmaceuticals Plc (AIM: AP.L), a bio-pharma company specializing in medical devices and compounds to control bleeding and accelerate the natural healing process. |
| Sector | Biopharmaceuticals |
| Date | February 22, 2008 |
| Analysis Gives HemCon a strong and immediate presence in Europe, and offers Alltracel inroads into the U.S. market. Also boosts HemCon's manufacturing capabilities through access to Alltracel factories, and offers access to a proprietary nanotechnology manufacturing process called Nanospider. Deal value -- $20.8m on ~ $50m of revenue. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |